PHYSIOMICS PLC (PYC) — Investor Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the PHYSIOMICS PLC investor presentation. Questions are encouraged and can be submitted via the q and a tab situated on the right hand side of your screen. Before we begin, I'd like to submit the following poll, which I kindly ask you to submit your responses to. I'd now like to hand over to CEO, Peter Sargent. Good afternoon. Thank you, Jack, and thank you all for for joining our IMC presentation today. So as most of you will know, my name is Peter Sargent. I'm the CEO here at PHYSIOMICS, and I'm joined here today by doctor Jim Millen, our nonexec chairman. So the purpose of this short presentation is firstly to provide a a brief update to the business and then provide some further context around the recent board of acquisition and why the current board does not feel that is in the best interest of the the the business. We'll be sure to keep the sure to keep the presentation short so we can spend a big part of this time answering as many questions as we can. I know that there's been quite a few questions already submitted, so we will be sure to kind of work through all those at the end of the presentation. You will also see that there is the ability to submit any further questions live as we go through the presentation or towards the end. So please do recommend that you do that. So many of you who have joined this call today will be already aware of the business. But for those of you who are less familiar with us, PHYSIOMICS at its core is a consultancy company providing highly technical data driven solutions into biotech and pharma clients, really to help support them accelerate and derisk their drug development programs, as well as help them meet their regulatory obligations. These consultancy services can be broken down into two mai...